has recommended GlaxoSmithKline’s (GSK) ZEJULA (niraparib) for some forms of ovarian, fallopian tube, and peritoneal cancer. Following a period of restricted access, the once-a-day capsule will ...
Glaxo (GSK) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
GSK has had another setback in its oncology business, after the FDA asked it to restrict use of its PARP inhibitor Zejula in ovarian, fallopian tube, or primary peritoneal cancer to patients with ...
Though GSK has put considerable effort into developing pharmacological treatments for gynecological cancers—including Zejula, which is approved by the FDA in ovarian cancer, and Jemperli for ...
Hosted on MSN11mon
GSK's Jemperli Cancer Drug Hits Primary Goal In Endometrial Cancer StudyGSK plc (NYSE: GSK) announced headline results ... (carboplatin and paclitaxel), followed by dostarlimab plus Zejula (niraparib) as maintenance therapy, for primary advanced or recurrent ...
Zacks.com on MSN1mon
GSK Q3 Earnings Top, Stock Down on Lowered '24 View for Vaccine SalesOncology sales rose 94%, driven by strong patient demand for Jemperli, Ojjaara and Zejula. Jemperli added £130 million to GSK ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback